Ad26.COV2.S(Janssen COVID-19 Vaccine)

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
 Sadoff J, Le Gars M, Shukarev G, et al. 〔N Engl J Med. 2021 May 13;384(19):1824-1835〕(査読済み)

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
 Stephenson KE, Le Gars M, Sadoff J, et al. 〔JAMA. 2021 Apr 20;325(15):1535-1544〕(査読済み)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination (Correspondence)
 Muir KL, Kallam A, Koepsell SA, et al. 〔N Engl J Med. 2021 May 20;384(20):1964-1965〕(査読済み)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
 Sadoff J, Gray G, Vandebosch A, et al. 〔N Engl J Med. 2021 Jun 10;384(23):2187-2201〕(査読済み)

US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021
 See I, Su JR, Lale A, et al.〔JAMA. 2021 Jun 22;325(24):2448-2456〕(査読済み)

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021
 Shay DK, Gee J, Su JR, et al. 〔MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):680-684〕(査読済み)

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study (Correspondence)
 Takuva S, Takalani A, Garrett N, et al. 〔N Engl J Med. 2021 Jun 2;NEJMc2107920〕(査読済み)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
 Alter G, Yu J, Lin J, et al. 〔Nature. 2021 Jun 9〕(査読済み)